Another Botox Competitor: Revance Prepares Longer-Lasting RT002 For BLA Submission
A claim that RT002's duration of efficacy surpasses the leading neurotoxin – Allergan's blockbuster Botox – will be put to the test when Revance seeks US FDA approval to treat frown lines in the first half of this year. The company's Botox biosimilar with Mylan also could move forward in 2019.
You may also be interested in...
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.
The company is preparing a staged launch for the neuromodulator in the aesthetics market, with a focus on educating select dermatologists first before expanding to 4,000 physician partners.
Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market.